Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
732.58
+0.62 (0.08%)
At close: Aug 29, 2025, 4:00 PM
732.25
-0.33 (-0.05%)
After-hours: Aug 29, 2025, 7:59 PM EDT
Eli Lilly Revenue
Eli Lilly had revenue of $15.56B in the quarter ending June 30, 2025, with 37.64% growth. This brings the company's revenue in the last twelve months to $53.26B, up 36.83% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$53.26B
Revenue Growth
+36.83%
P/S Ratio
12.37
Revenue / Employee
$1,133,151
Employees
47,000
Market Cap
657.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
LLY News
- 2 hours ago - Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study - Reuters
- 2 days ago - Eli Lilly Is Proof That Wall Street Stars Don't Have To Be Tech Titans - Benzinga
- 2 days ago - Eli Lilly joins forces with China tech giant to expand obesity drug market - Invezz
- 3 days ago - Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy. - Barrons
- 3 days ago - Stock Of The Day: Another Breakout For Eli Lilly? - Benzinga
- 3 days ago - Eli Lilly: In The Eye Of The Drug Pricing Storm - Expect Volatility, And Buy - Seeking Alpha
- 3 days ago - Eli Lilly: Orals Unlock The Next Wave Of Obesity Drug Adoption - Seeking Alpha
- 3 days ago - Eli Lilly: Why I'm Pairing It With My Novo Position - Seeking Alpha